Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

BioAge Labs, Inc. (BIOA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey ...